Trials / Completed
CompletedNCT03571308
A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
A Phase Ib/II Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- University Hospital Southampton NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
Previously untreated CD20 positive diffuse large B-cell lymphoma (DLBCL) requiring full course chemoimmunotherapy.
Detailed description
Open-label non-randomised phase Ib/II study conducted in two stages. Stage 1 will be dose escalation in a modified classical 6+6 design. Stage 2 will be an expansion cohort to gain additional information on safety and efficacy at the recommended phase II dose of acalabrutinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | R-CHOP + acalabrutinib | Patient will be given R-CHOP and acalabrutinib |
Timeline
- Start date
- 2017-06-02
- Primary completion
- 2020-01-02
- Completion
- 2023-08-31
- First posted
- 2018-06-27
- Last updated
- 2023-09-28
Locations
7 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03571308. Inclusion in this directory is not an endorsement.